

Other version: https://www.frontiersin.org/article/10.3389/fbioe.2020.00165/full
![]() |
How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept |
|
Authors | ||
Published in | Frontiers in bioengineering and biotechnology. 2020, vol. 8 | |
Abstract | Efficacy and safety of nanomedicines based on polymeric (bio)materials will benefit from a rational implementation of a Safe-by-Design (SbD) approach throughout their development. In order to achieve this goal, however, a standardization of preparation and characterization methods and their accurate reporting is needed. Focusing on the example of chitosan, a biopolymer derived from chitin and frequently used in drug and vaccine delivery vector preparation, this review discusses the challenges still to be met and overcome prior to a successful implementation of the SbD approach to the preparation of chitosan-based protein drug delivery systems | |
Keywords | Safe by design — Polymeric drug carriers — Chitosan — Insulin — Protein drug delivery | |
Identifiers | PMID: 32211394 | |
Full text |
![]() ![]() Other version: https://www.frontiersin.org/article/10.3389/fbioe.2020.00165/full |
|
Structures | ||
Research group | Biopharmacie | |
Citation (ISO format) | MARQUES, Cintia et al. How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept. In: Frontiers in Bioengineering and Biotechnology, 2020, vol. 8. doi: 10.3389/fbioe.2020.00165 https://archive-ouverte.unige.ch/unige:144873 |